Opinion|Videos|January 5, 2026
Xanomeline/Trospium Mechanism of Action, Efficacy, and Safety
Panelists discuss how the muscarinic pathway of xanomeline/trospium offers a safer, nondopaminergic approach to schizophrenia care.
Advertisement
Episodes in this series
Panelists discuss how xanomeline/trospium chloride introduces a paradigm shift in schizophrenia therapy through selective muscarinic receptor activity, avoiding dopamine blockade.
Panelists discuss how phase 3 EMERGENT-2 and EMERGENT-3 trials demonstrated its efficacy in reducing psychotic symptoms with minimal metabolic or neurologic adverse effects.
Panelists discuss how this mechanism may redefine treatment options for patients who experience poor tolerability or limited response to existing dopamine-based therapies.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
2
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
3
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
4
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
5